Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease

Abstract

Objectives:We prospectively compared the postvaccination immunity to messenger ribonucleic acid BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine of our pediatric patients over 12 years old with inflammatory bowel disease (IBD) to that of healthy controls and looked for predictors of its robustness. Methods: Anti-receptor binding domain, anti-spike S2, and anti-nucleocapsid immunoglobin-G (IgG) and immunoglobin-A levels were measured in 139 pediatric patients with IBD [65 fully vaccinated (2 doses), median age 16.3, interquartile range (IQR) 15.2-17.8 years, median time from vaccination (IQR) 61.0 (42.0-80.0) days] and 1744 controls (46, 37-57 years) using microblot array. Results: All IBD and control patients developed positive anti-receptor binding domain IgG antibodies at comparable titers. The proportion of observations with positive anti-spike S2 IgG was higher in patients with IBD than in controls [63% vs 21%, odds ratio 2.99 (1.51-5.90)], as was its titer [median (IQR) 485 (92-922) vs 79 [33-180] IU/mL]. Anti-receptor binding domain and anti-spike S2 IgG levels were associated with IBD status. We found an association between anti-spike S2 IgG levels and time since vaccination (β −4.85, 95% CI −7.14 to 2.71, P = 0.0001), history of SARS-CoV-2 polymerase chain reaction positivity (206.76, 95% CI 39.93-374.05, P = 0.0213), and anti-tumor necrosis factor treatment (−239.68, 95% CI −396.44-83.55, P = 0.0047). Forty-three percent of patients reported vaccination side effects (mostly mild). Forty-six percent of observations with positive anti-nucleocapsid IgG had a history of SARS-CoV-2 infection. Conclusions: Patients with IBD produced higher levels of postvaccination anti-spike S2 antibodies than controls. Previous SARS-CoV-2 infection is associated with higher production of postvaccination antibodies and antitumor necrosis factor treatment with lower production.

Humoral immune response and safety of SARS‐CoV‐2 vaccination in very early onset inflammatory bowel disease

“…Other studies have demonstrated that older children with IBD mount a robust antibody response to SARS-CoV-2 vaccination as well. 8,16,17 Moreover, similar to reports in adults with IBD 7 and older children, 8 severe vaccine-related AEs and IBD exacerbation following vaccination were uncommon.…”

Postvaccination Immunogenicity of COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease: Comment

“…We would like to share ideas on the publication “Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease” ( 1 ). Bronsky et al prospectively compared the postvaccination immunity to messenger ribonucleic acid BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine of their pediatric patients over 12 years old with IBD to that of healthy controls and looked for predictors of its robustness ( 1 ). Bronsky et al discovered that patients with IBD had higher levels of anti-spike S2 antibodies after vaccination than controls ( 1 ).…”

“…Bronsky et al prospectively compared the postvaccination immunity to messenger ribonucleic acid BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine of their pediatric patients over 12 years old with IBD to that of healthy controls and looked for predictors of its robustness ( 1 ). Bronsky et al discovered that patients with IBD had higher levels of anti-spike S2 antibodies after vaccination than controls ( 1 ). Bronsky et al concluded that prior SARS-CoV-2 infection is associated with increased postvaccination antibody production and anti-tumor necrosis factor treatment with decreased production ( 1 ).…”

“…Bronsky et al discovered that patients with IBD had higher levels of anti-spike S2 antibodies after vaccination than controls ( 1 ). Bronsky et al concluded that prior SARS-CoV-2 infection is associated with increased postvaccination antibody production and anti-tumor necrosis factor treatment with decreased production ( 1 ).…”

Response to Letter to the Editor: Post-Vaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease

“…On behalf of our research team, I would like to submit a short response to the Letter to the Editor (“Postvaccination Immunogenicity of COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease. : Comment”)( 1 ) concerning our original article published in JPGN named “Post-Vaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease.”( 2 )…”